<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5213">
  <stage>Registered</stage>
  <submitdate>7/09/2015</submitdate>
  <approvaldate>7/09/2015</approvaldate>
  <nctid>NCT02582697</nctid>
  <trial_identification>
    <studytitle>Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours</studytitle>
    <scientifictitle>Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours</scientifictitle>
    <utrn />
    <trialacronym>P3BEP</trialacronym>
    <secondaryid>ACTRN12613000496718</secondaryid>
    <secondaryid>ANZUP1302</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Germ Cell Tumor</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Testicular</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Other cancer types</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Bleomycin (active name: Bleomycin Sulfate)
Treatment: drugs - Etoposide
Treatment: drugs - Cisplatin
Treatment: drugs - Pegylated G-CSF (Pegfilgrastim)
Treatment: drugs - Filgrastim

Active Comparator: Standard Arm - Standard BEP - Participants 16 years or older will receive 4 cycles of Standard BEP as follows:
Bleomycin 30,000 IU IV weekly for 3 doses
Etoposide 100 mg/m2 IV on day 1 - 5
Cisplatin 20 mg/m2 IV on day 1 - 5
Pegylated G-CSF 6 mg SCI on day 6
Patients &lt; 16 years old and weighs = 45 kg will receive:
Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses
Etoposide 100 mg/m2 IV on day 1 - 5
Cisplatin 20 mg/m2 IV on day 1 - 5
Pegylated G-CSF 6 mg SCI on day 6
Patients &lt;16 years old and weighs &lt; 45 kg will receive:
Bleomycin *15,000 - 30,000 IU IV weekly for 3 doses
Etoposide 100 mg/m2 IV on day 1 - 5
Cisplatin 20 mg/m2 IV on day 1 - 5
Filgrastim 10mcg/kg/day on day 6, until post-nadir Absolute Neutrophil Count =1 x10^9/ L
The dose of bleomycin is decided by the treating physician and based on the patient's Body Surface Area.
Each cycle is 3 weeks (21 days).
The planned total duration of treatment is 12 weeks.

Experimental: Experimental Arm - Accelerated BEP - Participants 16years or older will receive 4 cycles of Accelerated BEP as follows:
Bleomycin 30,000 IU IV wkly for 2 doses
Etoposide 100 mg/m2 IV on day 1 - 5
Cisplatin 20 mg/m2 IV on day 1- 5
Pegylated G-CSF 6 mg SCI on day 6
Patients &lt;16years and weighs =45 kg will receive:
Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses
Etoposide 100 mg/m2 IV on day 1 - 5
Cisplatin 20 mg/m2 IV on day 1 - 5
Pegylated G-CSF 6 mg SCI on day 6
Patients &lt;16years and weighs &lt;45 kg will receive:
Bleomycin *15,000 - 30,000 IU IV wkly for 2 doses
Etoposide 100 mg/m2 IV on day 1 - 5
Cisplatin 20 mg/m2 IV on day 1 - 5
Filgrastim 10mcg/kg/day on day 6, until ANC =1 x10^9/ L
Each cycle is 2 weeks (14days)
Following 4xBEP cycles, patients will receive additional bleomycin as follows:
- Bleomycin *15,000 - 30,000 IU IV wkly for 4 doses
* The dose of bleomycin is decided by the treating physician and based on the patient's BSA.
The planned total duration is 12 weeks.


Treatment: drugs: Bleomycin (active name: Bleomycin Sulfate)
Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.
Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses.

Treatment: drugs: Etoposide
Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.
Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.

Treatment: drugs: Cisplatin
Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.
Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.

Treatment: drugs: Pegylated G-CSF (Pegfilgrastim)
Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.

Treatment: drugs: Filgrastim
Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count = 1.0 x 10^9/L, of a 21-day cycle for 4 cycles.
Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count = 1.0 x 10^9/L, of a 14-day cycle for 4 cycles.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Progression-free survival (disease progression or death) - PFS is measured from the date of randomisation until the criteria for disease progression are met (as defined in the protocol) or death. Participants who are not observed to progress nor die will be censored at the date of last follow-up</outcome>
      <timepoint>From randomisation up to disease progression or date of death whichever come first, assessed up to 5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Initial response assessment - The assessment of response of germ cell tumours is measured by the change in size of measurable tumour masses in combination with changes in serum tumour markers after chemotherapy treatment.</outcome>
      <timepoint>At end of chemotherapy treatment, treatment planned for 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Final response assessment - The assessment of response of germ cell tumours is measured by changes in serum tumour markers and imaging at 6 months from randomisation, or after any post-chemotherapy surgical resection or other intervention, whichever occurs last.</outcome>
      <timepoint>At 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events (worst grade according to NCI CTCAE v4.03) - The intensity of adverse events will be assessed using the NCI Common Terminology Criteria for Adverse Events version 4 (NCI CTCAE v4.03)</outcome>
      <timepoint>From start of chemotherapy until 30 days after last dose, an average of 4 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related quality of life - HR-QoL measures will include the EORTC core quality of life questionnaire (QLQ-C30), a 30-item cancer-specific questionnaire that is well-validated and available in many languages.</outcome>
      <timepoint>From date of randomisation until date of 18 month follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Health-related quality of life for testicular cancer - EORTC quality of life module for testicular cancer (QLQ-TC26), a disease-specific measure with 26 items about physical symptoms, sexual functioning and emotional issues.</outcome>
      <timepoint>From date of randomisation until date of 18 month follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment preference - A trial-specific preferences question will be used to determine if participants think they would prefer to be treated with accelerated BEP or standard BEP, assuming that they were equally effective.</outcome>
      <timepoint>From date of randomisation until date of 18 month follow-up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Delivered dose-intensity of chemotherapy (relative to standard BEP) - Delivered dose-intensity of cisplatin, etoposide and bleomycin will be assessed.</outcome>
      <timepoint>From start date of chemotherapy treatment until date of end of chemotherapy, an average of 12 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival - Overall survival is measured from the date of randomisation until death from any cause, or the date of last known follow-up alive.</outcome>
      <timepoint>From randomisation up to disease progression or date of death whichever come first, assessed up to 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age = 11 years and = 45 years on the date of randomisation

          2. Histologically or cytologically confirmed germ cell tumour (non-seminoma or seminoma);
             or Exceptionally raised tumour markers (AFP = 1000ng/mL and/or HCG = 5000 IU/L)
             without histologic or cytologic confirmation in the rare case where pattern of
             metastases consistent with GCT, high tumour burden, and a need to start therapy
             urgently

          3. Primary arising in testis, ovary, retro-peritoneum, or mediastinum

          4. Metastatic disease or non-testicular primary

          5. Intermediate or poor prognosis as defined by IGCCC classification3 (modified with
             different LDH criteria for intermediate risk non-seminoma, and inclusion of ovarian
             primaries). (See protocol for more information).

          6. Adequate bone marrow function with ANC =1.0 x 10^9/L, Platelet count =100 x 10^9/L

          7. Adequate liver function where bilirubin must be =1.5 x ULN, except participants with
             Gilbert's Syndrome where bilirubin must be =2.0 x ULN; ALT and AST must be =2.5 x ULN,
             except if the elevations are due to hepatic metastases, in which case ALT and AST must
             be = 5 x ULN

          8. Adequate renal function with estimated creatinine clearance of =60 ml/min according to
             the Cockcroft-Gault formula, unless calculated to be &lt; 60 ml/min or borderline in
             which case GFR should be formally measured, eg. with EDTA scan

          9. ECOG Performance Status of 0, 1, 2, or 3

         10. Study treatment both planned and able to start within 14 days of randomisation.

         11. Willing and able to comply with all study requirements, including treatment, timing
             and nature of required assessments

         12. Able to provide signed, written informed consent</inclusivecriteria>
    <inclusiveminage>11</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Other primary malignancy (EXCEPT adequately treated non-melanomatous carcinoma of the
             skin, germ cell tumour, or other malignancy treated at least 5 years previously with
             no evidence of recurrence)

          2. Previous chemotherapy or radiotherapy, except if patient has pure seminoma relapsing
             after adjuvant radiotherapy or adjuvant chemotherapy with 1-2 doses of single agent
             carboplatin or if patient has non-seminoma and poor prognosis by IGCCC criteria in the
             rare case where low-dose induction chemotherapy is given prior to registration because
             patient is not fit enough to receive protocol chemotherapy (eg. organ failure, vena
             cava obstruction, overwhelming burden of disease). In these instances acceptable
             regimens include cisplatin 20 mg/m^2 days 1-2 and etoposide 100 mg/m^2 days 1-2;
             carboplatin AUC 3 days 1-2 and etoposide 100 mg/m^2 days 1-2; or baby-BOP. Patients
             must meet all other inclusion and exclusion criteria at the time of registration.

             Additionally participants who need to start therapy urgently prior to completing
             study-specific baseline investigations may commence study chemotherapy prior to
             registration and randomisation. Such patients must be discussed with the coordinating
             centre prior to registration, and must be registered within 10 days of commencing
             study chemotherapy.

          3. Significant cardiac disease resulting in inability to tolerate IV fluid hydration for
             cisplatin

          4. Significant co-morbid respiratory disease that contraindicates the use of bleomycin

          5. Peripheral neuropathy = grade 2 or clinically significant sensorineural hearing loss
             or tinnitus

          6. Concurrent illness, including severe infection that may jeopardize the ability of the
             participant to undergo the procedures outlined in this protocol with reasonable safety

          7. Inadequate contraception. Men must use 2 effective methods of contraception, including
             use of a condom, during chemotherapy and for a year after completing chemotherapy.

          8. Known allergy or hypersensitivity to any of the study drugs

          9. Presence of any psychological, familial, sociological or geographical condition that
             in the opinion of the investigator would hamper compliance with the study protocol and
             follow-up schedule, including alcohol dependence or drug abuse

        The above inclusion and exclusion criteria will apply to stage 1 (n=150) and stage 2 (n=500
        including stage 1) of the study. All sites will participate in both stages of the study
        with the exception of the Children's Oncology Group who will be participate in stage 1
        only.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/02/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2023</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,TAS,VIC,WA</recruitmentstate>
    <hospital>Calvary Mater Newcastle - Newcastle</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>Prince of Wales Hospital - Sydney</hospital>
    <hospital>Chris O'Brien Lifehouse - Sydney</hospital>
    <hospital>Macquarie Cancer Clinical Trials - Sydney</hospital>
    <hospital>Concord Repatriation General Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Sydney</hospital>
    <hospital>Nepean Hospital - Sydney</hospital>
    <hospital>Tweed Hospital - Tweed Heads</hospital>
    <hospital>SAN Clinical Trials Unit - Wahroonga</hospital>
    <hospital>Royal Brisbane &amp; Women's Hospital - Brisbane</hospital>
    <hospital>Princess Alexandra - Woolloongabba</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Flinders Medical Centre - Bedford Park</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Box Hill Hospital - Box Hill</hospital>
    <hospital>Peter MacCallum Cancer Centre - East Melbourne</hospital>
    <hospital>Austin Health - Heidelberg</hospital>
    <hospital>Sunshine Hospital - St Albans</hospital>
    <hospital>Border Medical Oncology - Wodonga</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2065 - St Leonards</postcode>
    <postcode>2031 - Sydney</postcode>
    <postcode>2050 - Sydney</postcode>
    <postcode>2109 - Sydney</postcode>
    <postcode>2139 - Sydney</postcode>
    <postcode>2145 - Sydney</postcode>
    <postcode>2751 - Sydney</postcode>
    <postcode>2485 - Tweed Heads</postcode>
    <postcode>2076 - Wahroonga</postcode>
    <postcode>4029 - Brisbane</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>7000 - Hobart</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3002 - East Melbourne</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3021 - St Albans</postcode>
    <postcode>3690 - Wodonga</postcode>
    <postcode>6847 - Murdoch</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Palmerston North</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian and New Zealand Urogenital and Prostate Cancer Trials Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cambridge University Hospitals NHS Foundation Trust</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Trials Ireland</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Children's Oncology Group</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Dana-Farber Cancer Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Southern California</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether accelerated BEP chemotherapy is more
      effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic
      germ cell tumours.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02582697</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Grimison</name>
      <address>Chris O'Brien Lifehouse</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>P3BEP Trial Coordinator</name>
      <address />
      <phone>+6195625000</phone>
      <fax />
      <email>p3bep@ctc.usyd.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>